ClinicalTrials.gg
CompletedNCT04929379PERL-FENOUpdated Nov 10, 2026Results posted

A Pilot Study of Fenofibrate to Prevent Kidney Function Loss in Type 1 Diabetes

A Phase 2 interventional study of Fenofibrate and Placebo in Diabetic Nephropathies, sponsored by Alessandro Doria. Completed at 4 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Alessandro Doria · Phase 2, Interventional, and Treatment

How we know

Updated Nov 10, 2026Now CompletedResults posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 153 studies in Diabetic Nephropathies with a site in United States — 22 open to participants now, 32 under way, 1 of them phase 3. Diabetic Nephropathies · United States.

Enrollment
89th of 120
35 · median 79
Started
2022
with 10 others
Phase 2
54 of 153
5 open now
Registered
116th of 153
by date
Lead sponsor
3 of 153
Alessandro Doria

Among the 153 studies in Diabetic Nephropathies with a site in United States, this one is the 89th largest by enrollment of the 120 interventional ones that give a count, is one of 11 that started in 2022, is one of 54 in phase 2, and was the 116th registered.

Diabetic Nephropathies

544 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.

Browse Diabetic Nephropathies studies →

Open to participants now

22 of the 153 studies in Diabetic Nephropathies with a site in United States are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 50 Diabetic Nephropathies studies recruiting now, 23 (46%) set no upper age limit and 16 (32%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 153 studies in Diabetic Nephropathies with a site in United States, or all of them as a file.
02

Study summary

Diabetic kidney disease remains the leading cause of end-stage kidney disease (ESKD), rising in frequency in parallel with the epidemic of diabetes worldwide. The estimated lifetime risk of kidney disease in persons with type 1 diabetes (T1D) has been reported to be as high as 50-70%, although risk may be lower in excellent care environments. Two previous studies have suggested that a generic drug used to lower fats in blood (fenofibrate) may protect the kidney from damage due to diabetes. These data, however, were obtained among people with type 2 diabetes with clinical characteristics optimized for cardiovascular studies. Thus, a clinical trial specifically designed to evaluate the effects on the kidney is required to firmly show that this drug can prevent kidney damage in T1D. The goals of the present pilot study are to demonstrate the feasibility of such trial, gather essential information for designing and planning this study, and generate preliminary data. To this end, 40 participants with T1D and early-to-moderate diabetic kidney disease (DKD), at high risk of ESKD, will be enrolled at two clinical sites and assigned in a 1:1 ratio to treatment with fenofibrate or placebo for 18 months. Kidney function will be measured at the beginning and at the end of the study to evaluate the effect of fenofibrate.

Read the detailed description

Despite improvements in the past 20 years in glycemic and blood pressure control, and the introduction of "reno-protective" drugs such as renin-angiotensin system blockers (RASB), the overall incidence of end-stage kidney disease (ESKD) in type 1 diabetes (T1D) remains high. To seek new treatments to prevent diabetic kidney disease (DKD) and/or slow its progression to ESKD in T1D, the investigators have established a unique consortium of high-quality academic centers, which has been named PERL (Preventing Early Renal Function Loss in Diabetes) to emphasize the focus on intervening relatively early in the course of DKD in T1D, when renal damage can more likely be slowed or stopped. Findings from the FIELD and ACCORD trials suggest a reno-protective effect of the PPAR-alpha agonist fenofibrate, raising the exciting possibility of using this inexpensive generic drug to prevent GFR decline in persons with T1D. These data, however, were obtained through post-hoc analyses of type 2 diabetes (T2D) populations with clinical characteristics optimized for CVD studies. Thus, a clinical trial specifically designed to evaluate effects on GFR decline is required to firmly establish a DKD indication for fenofibrate in T1D. As a first step, the investigators are conducting a pilot study including 40 participants with T1D and early-to-moderate DKD, at high risk of ESKD, who will be enrolled at two of the PERL sites and randomized in a 1:1 ratio to treatment with fenofibrate or placebo for 18 months, followed by a two-month washout. The goal of this pilot study are to:

  1. Define the nature of the acute effect of fenofibrate on kidney function. It remains unclear whether the eGFR reduction observed at the beginning of fenofibrate treatment is an artifact of fenofibrate-induced changes in creatinine production and/or renal tubular handling, or corresponds to an actual reduction in GFR. This controversy, which has crucial implications for the pivotal trial design, will be resolved by directly measuring GFR by plasma iohexol disappearance - a methodology in which PERL sites are experienced.
  2. Generate further data on the long-term effects of fenofibrate on GFR decline in persons with T1D and DKD who are at high risk of rapid GFR decline and ESKD. The positive effects of fenofibrate in FIELD and ACCORD were observed in individuals who were not selected for having DKD and who, if untreated, had a mean GFR decline barely above the physiological decline due to aging. To make a compelling case for a pivotal trial for kidney outcomes, it is crucial to generate preliminary data on the effectiveness and safety of this drug in persons selected for having DKD and being rapidly progressing towards ESKD.
  3. Determine the effects of fenofibrate on biomarkers of increased risk of fast GFR decline. A salutary effect of fenofibrate on one or more of these biomarkers will corroborate any trend of a fenofibrate benefit identified in Aim 2.

The results of this pilot will allow the investigators to seek support for a pivotal trial to establish a kidney indication for fenofibrate in T1D.

03

Conditions studied

  • Diabetic Nephropathies

Keywords

  • type 1 diabetes
  • diabetic kidney disease
  • fibrates
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 and 70 years of age, inclusive.
  • Type 1 diabetes (T1D) continuously treated with insulin within one year from diagnosis. If the onset was after age 35, the presence of one or more of the following will also be required: a. documentation of the presence of circulating T1D-associated autoantibodies at diagnosis or at any other time; b. history of hospitalization for DKA; c. plasma C-peptide below the limit of detection with standard assay (with concurrent blood glucose >100 mg/dl)
  • Duration of T1D ≥ 8 years.
  • Diabetic kidney disease at high risk of progression to ESKD, defined as follows: PERL allopurinol study participants: iGFR decline ≥3 ml/min/1.73 m2/year during the trial and micro- or macro-albuminuria (urinary albumin excretion rate [AER]=30-5000 mg/24 hr or albumin creatinine ratio [ACR]=30-5000 mg/g if not on renin-angiotensin system blocker (RASB) agents, or AER=18-5000 mg/24 hr or ACR 18-5000 mg/g range, if on RASB agents) on at least two occasions during the PERL allopurinol trial. All others participants: macroalbuminuria (AER=100-5000 mg/24 hrs or ACR=100-5000 mg/g) on two occasions during the three years before screening and/or at screening;
  • Estimated (eGFR) based on serum creatinine between 40 and 99.9 ml/min/1.73 m2 at screening. The upper and the lower limits should be decreased by 1 ml/min/1.73 m2 for each year over age 60 (with a lower limit of 35 ml/min/1.73m2) and by 10 ml/min/1.73 m2 for strict vegans.
  • Valid baseline (Visit 2) iGFR measurement.
  • Current treatment with RASB, unless ;
  • Willing and able to comply with schedule of events and protocol requirements, including written .

Exclusion criteria

Exclusion Criteria:

  • Renal transplant or dialysis;
  • Non-diabetic kidney disease;
  • Allergy to fibrates or iodine containing substances;
  • Current therapy with fibrates or other PPAR-α agonists;
  • Specific or indications for fibrates;
  • History of photosensitive skin rash or myositis;
  • Persistent elevated unexplained blood creatinine phosphokinase level >3 times the ;
  • History of pancreatitis, deep vein thrombosis (DVT) or pulmonary embolism;
  • History of cholelithiasis unless gallbladder has been removed;
  • Cancer treatment (excluding non-melanoma skin cancer treated by excision) within two years of screening;
  • Current or past history of decompensated cirrhosis (defined as variceal bleeding, ascites, or hepatic encephalopathy and/or diagnosis of cirrhosis based on liver , imaging, or elastography and/or aspartate or (AST or ALT) >2 times the upper limit of normal at screening and/or total >1.3 times the upper limit of normal at screening (in the case of Gilbert syndrome, direct bilirubin >1.5 times the upper limit of normal at screening);
  • History of acquired immune deficiency syndrome or (HIV) infection;
  • concentration \<11 g/dL (males), \<10 g/dL (females) or count \<100,000/mm3 at screening;
  • Alcohol or drug abuse in the past 6 months;
  • Blood donation within 3 months of screening;
  • Breastfeeding, pregnancy, or unwillingness to be on during the trial;
  • Poor mental function or any reasons to expect difficulty in complying with study requirements;
  • Serious medical problems other than diabetes, e.g. congestive heart failure, pulmonary insufficiency;
  • Participation in another interventional study.
  • Being incarcerated.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Fenofibrate

    145 mg oral fenofibrate daily for 76 weeks. Dosage is decreased to 48 mg daily if iGFR is or is estimated to be below 30 ml/min/1.73 m2.

    Drug: Fenofibrate

  • Placebo comparator
    Placebo

    Inactive tablets identical to fenofibrate

    Other: Placebo

Interventions

  • 145 mg oral fenofibrate daily for 76 weeks. Dosage is decreased to 48 mg daily if iGFR is or is estimated to be below 30 ml/min/1.73 m2.

  • OtherPlacebo

    Inactive tablets identical to fenofibrate

06

What researchers measure

Primary outcomes

  1. Baseline-adjusted iGFR at 8 Weeks After Randomization

    GFR measured by iohexol plasma disappearance (ml/min/1.73 m2), adjusted by its baseline value

    Time frame: 8 weeks after randomization

  2. Baseline-adjusted iGFR at the End of the Drug Wash-out Period

    GFR measured by iohexol plasma disappearance (ml/min/1.73 m2), adjusted by its baseline value

    Time frame: 84 weeks after randomization

  3. Baseline-adjusted Serum Levels of CD160 at the End of the Drug-wash-out Period (Week 84).

    CD160 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 84 weeks after randomization

  4. Baseline-adjusted Serum Levels of CD27 at the End of the Drug-wash-out Period (Week 84).

    CD27 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 84 weeks from randomization

  5. Baseline-adjusted Serum Levels of DLL1 at the End of the Drug-wash-out Period (Week 84).

    DLL1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 84 weeks from randomization

  6. Baseline-adjusted Serum Levels of EDA2R at the End of the Drug-wash-out Period (Week 84).

    EDA2R is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 84 weeks from randomization

  7. Baseline-adjusted Serum Levels of EFNA4 at the End of the Drug-wash-out Period (Week 84).

    EFNA4 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 84 weeks from randomization

  8. Baseline-adjusted Serum Levels of EPHA2 at the End of the Drug-wash-out Period (Week 84).

    EPHA2 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 84 weeks from randomization

  9. Baseline-adjusted Serum Levels of GFR-alpha-1 at the End of the Drug-wash-out Period (Week 84).

    GFR-alpha-1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 84 weeks from randomization

  10. Baseline-adjusted Serum Levels of IL-1RT1 at the End of the Drug-wash-out Period (Week 84).

    IL-1RT1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 84 weeks from randomization

  11. Baseline-adjusted Serum Levels of KIM1 at the End of the Drug-wash-out Period (Week 84).

    KIM1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 84 weeks from randomization

  12. Baseline-adjusted Serum Levels of LAYN at the End of the Drug-wash-out Period (Week 84).

    LAYN is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 84 weeks from randomization

  13. Baseline-adjusted Serum Levels of LTBR at the End of the Drug-wash-out Period (Week 84).

    LTBR is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 84 weeks from randomization

  14. Baseline-adjusted Serum Levels of PI3 at the End of the Drug-wash-out Period (Week 84).

    PI3 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 84 weeks from randomization

  15. Baseline-adjusted Serum Levels of PVRL4 at the End of the Drug-wash-out Period (Week 84).

    PVRL4 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 84 weeks from randomization

  16. Baseline-adjusted Serum Levels of RELT at the End of the Drug-wash-out Period (Week 84).

    RELT is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 84 weeks from randomization

  17. Baseline-adjusted Serum Levels of SYND1 at the End of the Drug-wash-out Period (Week 84).

    SYND1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 84 weeks from randomization

  18. Baseline-adjusted Serum Levels of TNFR1 at the End of the Drug-wash-out Period (Week 84).

    TNFR1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml

    Time frame: 84 weeks from randomization

  19. Baseline-adjusted Serum Levels of TNFR2 at the End of the Drug-wash-out Period (Week 84).

    TNFR2 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml

    Time frame: 84 weeks from randomization

  20. Baseline-adjusted Serum Levels of TNFRSF10A at the End of the Drug-wash-out Period (Week 84).

    TNFRSF10A is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 84 weeks from randomization

  21. Baseline-adjusted Serum Levels of TNFRSF4 at the End of the Drug-wash-out Period (Week 84).

    TNFRSF4 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 84 weeks from randomization

  22. Baseline-adjusted Serum Levels of TNFRSF6B at the End of the Drug-wash-out Period (Week 84).

    TNFRSF6B is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 84 weeks from randomization

  23. Baseline-adjusted Serum Levels of WFDC2 at the End of the Drug-wash-out Period (Week 84).

    WFDC2 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 84 weeks from randomization

Secondary outcomes

  1. Baseline-adjusted eGFR-SCr at 8 Weeks After Randomization

    GFR estimated from serum creatinine (ml/min/1.73 m2) using the CKD-EPI equation, adjusted by its baseline value

    Time frame: 8 weeks after randomization

  2. Baseline-adjusted eGFR-CysC at 8 Weeks After Randomization

    GFR estimated from serum cystatin C (ml/min/1.73 m2) using the CKD-EPI equation, adjusted by its baseline value

    Time frame: 8 weeks after randomization

  3. Baseline-adjusted uAER at 8 Weeks After Randomization

    Urinary Albumin excretion rate (uAER, μg/min) based on overnight urine collection, adjusted by its baseline value

    Time frame: 8 weeks after randomization

  4. Baseline-adjusted Creatinine Clearance at 8 Weeks After Randomization

    Creatinine clearance (ml/min) based on overnight urine collection, adjusted by its baseline value

    Time frame: 8 weeks after randomization

  5. Baseline-adjusted ERPF at 8 Weeks After Randomization

    Effective renal plasma flow (ml/min) measured by means of para-aminohippurate infusion, adjusted by its baseline value

    Time frame: 8 weeks after randomization

  6. Baseline-adjusted Afferent Renal Arteriolar Resistance at 8 Weeks After Randomization

    Afferent renal arteriolar resistance (dyne/s/cm5) measured by means of para-aminohippurate infusion, adjusted by its baseline value

    Time frame: 8 weeks after randomization

  7. Baseline-adjusted Efferent Renal Arteriolar Resistance at 8 Weeks After Randomization

    Efferent renal arteriolar resistance (dyne/s/cm5) measured by means of para-aminohippurate infusion, adjusted by its baseline value

    Time frame: 8 weeks after randomization

  8. Baseline-adjusted Glomerular Hydrostatic Pressure at 8 Weeks After Randomization

    Glomerular hydrostatic pressure (mmHg) measured by means of para-aminohippurate infusion, adjusted by its baseline value

    Time frame: 8 weeks after randomization

  9. Baseline-adjusted Glomerular Filtration Pressure at 8 Weeks After Randomization

    Glomerular filtration pressure (mmHg) measured by means of para-aminohippurate infusion, adjusted by its baseline value

    Time frame: 8 weeks after randomization

  10. Baseline-adjusted eGFR-SCr at the End of the Wash-out Period

    GFR estimated from serum creatinine (ml/min/1.73 m2) using the CKD-EPI equation, adjusted by its baseline value

    Time frame: 84 weeks after randomization

  11. Baseline-adjusted eGFR-CysC at the End of the Wash-out Period

    GFR estimated from serum cystatin C (ml/min/1.73 m2) using the CKD-EPI equation, adjusted by its baseline value

    Time frame: 84 weeks after randomization

  12. Baseline-adjusted uAER at the End of the Wash-out Period

    Urinary albumin excretion rate (uAER, μg/min) based on overnight urine collection, adjusted by its baseline value

    Time frame: 84 weeks after randomization

  13. Baseline-adjusted iGFR at the End of Treatment

    GFR measured by iohexol plasma disappearance (ml/min/1.73 m2), adjusted by its baseline value

    Time frame: 76 weeks after randomization

  14. Baseline-adjusted eGFR-SCr at the End of Treatment

    GFR estimated from serum creatinine (ml/min/1.73 m2) using the CKD-EPI equation, adjusted by its baseline value

    Time frame: 76 weeks after randomization

  15. Baseline-adjusted eGFR-CysC at the End of Treatment

    GFR estimated from serum cystatin C (ml/min/1.73 m2) using the CKD-EPI equation, adjusted by its baseline value

    Time frame: 76 weeks after randomization

  16. Baseline-adjusted uAER at the End of Treatment

    Urinary albumin excretion rate (uAER, μg/min) based on overnight urine collection, adjusted by its baseline value

    Time frame: 76 weeks after randomization

  17. Week 8-adjusted iGFR at the End of Treatment

    GFR measured by iohexol plasma disappearance (ml/min/1.73 m2), adjusted by its value at week 8

    Time frame: 76 weeks after randomization

  18. Week 8-adjusted eGFR-SCr at the End of Treatment

    GFR estimated from serum creatine (ml/min/1.73 m2) using the CKD-EPI equation, adjusted by its value at week 8

    Time frame: 76 weeks from randomization

  19. Week 8-adjusted eGFR-CysC at the End of Treatment

    GFR estimated from serum cystatin C (ml/min/1.73 m2) using the CKD-EPI equation, adjusted by its value at week 8

    Time frame: 76 weeks after randomization

  20. Week 8-adjusted uAER at the End of Treatment

    Urinary Albumin excretion rate (uAER, μg/min) based on overnight urine collection, adjusted by its value at week 8

    Time frame: 76 weeks after randomization

  21. eGFR-SCr Trajectory

    Trajectory of GFR estimated from serum creatinine (ml/min/1.73 m2/year) using the CKD-EPI equation

    Time frame: 8 to 76 weeks from randomization

  22. eGFR-SCys Trajectory

    Trajectory of GFR estimated from serum cystatin C (ml/min/1.73 m2/year) using the CKD-EPI equation

    Time frame: 8 to 76 weeks from randomization

  23. Baseline-adjusted Serum Levels of CD160 at the End of the Treatment Period (Week 76).

    CD160 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 76 weeks after randomization

  24. Baseline-adjusted Serum Levels of CD27 at the End of the Treatment Period (Week 76).

    CD27 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 76 weeks after randomization

  25. Baseline-adjusted Serum Levels of DLL1 at the End of the Treatment Period (Week 76).

    DLL1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 76 weeks after randomization

  26. Baseline-adjusted Serum Levels of EDA2R at the End of the Treatment Period (Week 76).

    EDA2R is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 76 weeks after randomization

  27. Baseline-adjusted Serum Levels of EFNA4 at the End of the Treatment Period (Week 76).

    EFNA4 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 76 weeks after randomization

  28. Baseline-adjusted Serum Levels of EPHA2 at the End of the Treatment Period (Week 76).

    EPHA2 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 76 weeks after randomization

  29. Baseline-adjusted Serum Levels of GFR-alpha-1 at the End of the Treatment Period (Week 76).

    GFR-alpha-1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 76 weeks after randomization

  30. Baseline-adjusted Serum Levels of IL-1RT1 at the End of the Treatment Period (Week 76).

    IL-1RT1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 76 weeks after randomization

  31. Baseline-adjusted Serum Levels of KIM1 at the End of the Treatment Period (Week 76).

    KIM1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 76 weeks after randomization

  32. Baseline-adjusted Serum Levels of LAYN at the End of the Treatment Period (Week 76).

    LAYN is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 76 weeks after randomization

  33. Baseline-adjusted Serum Levels of LTBR at the End of the Treatment Period (Week 76).

    LTBR is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 76 weeks after randomization

  34. Baseline-adjusted Serum Levels of PI3 at the End of the Treatment Period (Week 76).

    PI3 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 76 weeks after randomization

  35. Baseline-adjusted Serum Levels of PVRL4 at the End of the Treatment Period (Week 76).

    PVRL4 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 76 weeks after randomization

  36. Baseline-adjusted Serum Levels of RELT at the End of the Treatment Period (Week 76).

    RELT is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 76 weeks after randomization

  37. Baseline-adjusted Serum Levels of SYND1 at the End of the Treatment Period (Week 76).

    SYND1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 76 weeks after randomization

  38. Baseline-adjusted Serum Levels of TNFR1 at the End of the Treatment Period (Week 76).

    TNFR1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 76 weeks after randomization

  39. Baseline-adjusted Serum Levels of TNFR2 at the End of the Treatment Period (Week 76).

    TNFR2 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 76 weeks after randomization

  40. Baseline-adjusted Serum Levels of TNFRSF10A at the End of the Treatment Period (Week 76).

    TNFRSF10A is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 76 weeks after randomization

  41. Baseline-adjusted Serum Levels of TNFRSF4 at the End of the Treatment Period (Week 76).

    TNFRSF4 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 76 weeks after randomization

  42. Baseline-adjusted Serum Levels of TNFRSF6B at the End of the Treatment Period (Week 76).

    TNFRSF6B is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 76 weeks after randomization

  43. Baseline-adjusted Serum Levels of WFDC2 at the End of the Treatment Period (Week 76).

    WFDC2 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 76 weeks after randomization

  44. Week 8-adjusted Serum Levels of CD160 at the End of the Treatment Period (Week 76).

    CD160 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 76 weeks after randomization

  45. Week 8-adjusted Serum Levels of CD27 at the End of the Treatment Period (Week 76).

    CD27 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 76 weeks after randomization

  46. Week 8-adjusted Serum Levels of DLL1 at the End of the Treatment Period (Week 76).

    DLL1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 76 weeks after randomization

  47. Week 8-adjusted Serum Levels of EDA2R at the End of the Treatment Period (Week 76).

    EDA2R is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 76 weeks after randomization

  48. Week 8-adjusted Serum Levels of EFNA4 at the End of the Treatment Period (Week 76).

    EFNA4 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 76 weeks after randomization

  49. Week 8-adjusted Serum Levels of EPHA2 at the End of the Treatment Period (Week 76).

    EPHA2 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 76 weeks after randomization

  50. Week 8-adjusted Serum Levels of GFR-alpha-1 at the End of the Treatment Period (Week 76).

    GFR-alpha-1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 76 weeks after randomization

  51. Week 8-adjusted Serum Levels of IL-1RT1 at the End of the Treatment Period (Week 76).

    IL-1RT1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 76 weeks after randomization

  52. Week 8-adjusted Serum Levels of KIM1 at the End of the Treatment Period (Week 76).

    KIM1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 76 weeks after randomization

  53. Week 8-adjusted Serum Levels of LAYN at the End of the Treatment Period (Week 76).

    LAYN is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 76 weeks after randomization

  54. Week 8-adjusted Serum Levels of LTBR at the End of the Treatment Period (Week 76).

    LTBR is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 76 weeks after randomization

  55. Week 8-adjusted Serum Levels of PI3 at the End of the Treatment Period (Week 76).

    PI3 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 76 weeks after randomization

  56. Week 8-adjusted Serum Levels of PVRL4 at the End of the Treatment Period (Week 76).

    PVRL4 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 76 weeks after randomization

  57. Week 8-adjusted Serum Levels of RELT at the End of the Treatment Period (Week 76).

    RELT is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 76 weeks after randomization

  58. Week 8-adjusted Serum Levels of SYND1 at the End of the Treatment Period (Week 76).

    SYND1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 76 weeks after randomization

  59. Week 8-adjusted Serum Levels of TNFR1 at the End of the Treatment Period (Week 76).

    TNFR1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 76 weeks after randomization

  60. Week 8-adjusted Serum Levels of TNFR2 at the End of the Treatment Period (Week 76).

    TNFR2 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 76 weeks after randomization

  61. Week 8-adjusted Serum Levels of TNFRSF10A at the End of the Treatment Period (Week 76).

    TNFRSF10A is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 76 weeks after randomization

  62. Week 8-adjusted Serum Levels of TNFRSF4 at the End of the Treatment Period (Week 76).

    TNFRSF4 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 76 weeks after randomization

  63. Week 8-adjusted Serum Levels of TNFRSF6B at the End of the Treatment Period (Week 76).

    TNFRSF6B is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 76 weeks after randomization

  64. Week 8-adjusted Serum Levels of WFDC2 at the End of the Treatment Period (Week 76).

    WFDC2 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

    Time frame: 76 weeks after randomization

07

Results

Posted Nov 10, 2026
Limitations and caveats
Power of tests for Aims 2 and 3 was limited due to the very small sample size of this pilot study.

Participant flow

Participants were enrolled at two locations (Joslin Diabetes Center, Boston, MA and U. of Michigan, Ann Arbor, MI

8 weeks of treatment (Aim 1))
Participant flow — 8 weeks of treatment (Aim 1))
MilestoneFenofibratePlacebo
Started1718
Completed1617
Not completed11
Withdrew: Withdrawal by subject10
Withdrew: Physician decision01
8 to 76 weeks of treatment (Aims 2 -3)
Participant flow — 8 to 76 weeks of treatment (Aims 2 -3)
MilestoneFenofibratePlacebo
Started1617
Completed1013
Not completed64
Withdrew: Withdrawal by subject31
Withdrew: Lost to follow-up10
Withdrew: Enrolled in abbreviated protocol ending at week 812
Withdrew: Early study site closure11
Washout (weeks 76 to 84) (Aims 2 -3)
Participant flow — Washout (weeks 76 to 84) (Aims 2 -3)
MilestoneFenofibratePlacebo
Started1013
Completed1011
Not completed02
Withdrew: Withdrawal by subject01
Withdrew: Lost to follow-up01

Outcome measures

PrimaryBaseline-adjusted iGFR at 8 Weeks After Randomization

GFR measured by iohexol plasma disappearance (ml/min/1.73 m2), adjusted by its baseline value

Time frame:
8 weeks after randomization
Reported as:
Least squares mean · ml/min/1.73m2
Baseline-adjusted iGFR at 8 Weeks After Randomization
ml/min/1.73m2FenofibratePlacebo
Baseline-adjusted iGFR at 8 Weeks After Randomization57.9 (55.3 to 60.4)63.1 (60.6 to 65.6)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.007 · Mean difference (final values): -5.2 · 95% CI -8.7 to -1.7
PrimaryBaseline-adjusted iGFR at the End of the Drug Wash-out Period

GFR measured by iohexol plasma disappearance (ml/min/1.73 m2), adjusted by its baseline value

Time frame:
84 weeks after randomization
Reported as:
Least squares mean · ml/min/1.73m2
Baseline-adjusted iGFR at the End of the Drug Wash-out Period
ml/min/1.73m2FenofibratePlacebo
Baseline-adjusted iGFR at the End of the Drug Wash-out Period62.4 (56.7 to 68.2)61.9 (56.4 to 67.5)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.90 · Mean difference (net): 0.5 · 95% CI -7.3 to 8.3
SecondaryBaseline-adjusted eGFR-SCr at 8 Weeks After Randomization

GFR estimated from serum creatinine (ml/min/1.73 m2) using the CKD-EPI equation, adjusted by its baseline value

Time frame:
8 weeks after randomization
Reported as:
Least squares mean · ml/min/1.73m2
Baseline-adjusted eGFR-SCr at 8 Weeks After Randomization
ml/min/1.73m2FenofibratePlacebo
Baseline-adjusted eGFR-SCr at 8 Weeks After Randomization61.0 (57.3 to 64.8)70.3 (66.6 to 73.9)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.0014 · Mean difference (net): -9.2 · 95% CI -14.3 to -4.1
SecondaryBaseline-adjusted eGFR-CysC at 8 Weeks After Randomization

GFR estimated from serum cystatin C (ml/min/1.73 m2) using the CKD-EPI equation, adjusted by its baseline value

Time frame:
8 weeks after randomization
Reported as:
Least squares mean · ml/min/1.73m2
Baseline-adjusted eGFR-CysC at 8 Weeks After Randomization
ml/min/1.73m2FenofibratePlacebo
Baseline-adjusted eGFR-CysC at 8 Weeks After Randomization56.6 (52.8 to 60.4)60.8 (57.1 to 64.5)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.126 · Mean difference (net): -4.2 · 95% CI -9.4 to 1.0
SecondaryBaseline-adjusted uAER at 8 Weeks After Randomization

Urinary Albumin excretion rate (uAER, μg/min) based on overnight urine collection, adjusted by its baseline value

Time frame:
8 weeks after randomization
Reported as:
Geometric least squares mean · μg/min
Baseline-adjusted uAER at 8 Weeks After Randomization
μg/minFenofibratePlacebo
Baseline-adjusted uAER at 8 Weeks After Randomization83.1 (62.2 to 111.0)128.1 (95.2 to 172.4)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.048 · Uaer fenofibrate to placebo ratio: 0.65 · 95% CI 0.43 to 0.98
SecondaryBaseline-adjusted Creatinine Clearance at 8 Weeks After Randomization

Creatinine clearance (ml/min) based on overnight urine collection, adjusted by its baseline value

Time frame:
8 weeks after randomization
Reported as:
Least squares mean · ml/min
Baseline-adjusted Creatinine Clearance at 8 Weeks After Randomization
ml/minFenofibratePlacebo
Baseline-adjusted Creatinine Clearance at 8 Weeks After Randomization95.4 (79.8 to 111.0)93.8 (77.6 to 110)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.89 · Mean difference (net): 1.6 · 95% CI -21.0 to 24.1
SecondaryBaseline-adjusted ERPF at 8 Weeks After Randomization

Effective renal plasma flow (ml/min) measured by means of para-aminohippurate infusion, adjusted by its baseline value

Time frame:
8 weeks after randomization
Reported as:
Least squares mean · ml/min/1.73 m2
Baseline-adjusted ERPF at 8 Weeks After Randomization
ml/min/1.73 m2FenofibratePlacebo
Baseline-adjusted ERPF at 8 Weeks After Randomization561.6 (483.4 to 639.8)501.2 (420.6 to 581.7)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.30 · Mean difference (net): 60.4 · 95% CI -51.2 to 172.1
SecondaryBaseline-adjusted Afferent Renal Arteriolar Resistance at 8 Weeks After Randomization

Afferent renal arteriolar resistance (dyne/s/cm5) measured by means of para-aminohippurate infusion, adjusted by its baseline value

Time frame:
8 weeks after randomization
Reported as:
Least squares mean · dyne/s/cm5
Baseline-adjusted Afferent Renal Arteriolar Resistance at 8 Weeks After Randomization
dyne/s/cm5FenofibratePlacebo
Baseline-adjusted Afferent Renal Arteriolar Resistance at 8 Weeks After Randomization4396 (3732 to 5060)4234 (3548 to 4920)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.74 · Mean difference (net): 162 · 95% CI -794 to 1118
SecondaryBaseline-adjusted Efferent Renal Arteriolar Resistance at 8 Weeks After Randomization

Efferent renal arteriolar resistance (dyne/s/cm5) measured by means of para-aminohippurate infusion, adjusted by its baseline value

Time frame:
8 weeks after randomization
Reported as:
Least squares mean · dyne/sec/cm5
Baseline-adjusted Efferent Renal Arteriolar Resistance at 8 Weeks After Randomization
dyne/sec/cm5FenofibratePlacebo
Baseline-adjusted Efferent Renal Arteriolar Resistance at 8 Weeks After Randomization1167 (1015 to 1320)1312 (1156 to 1467)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.20 · Mean difference (net): -144 · 95% CI -359 to 70
  • Fenofibrate vs Placebo · ANCOVA · p = 0.20 · Mean difference (net): -144 · 95% CI -358.5 to 70.5
SecondaryBaseline-adjusted Glomerular Hydrostatic Pressure at 8 Weeks After Randomization

Glomerular hydrostatic pressure (mmHg) measured by means of para-aminohippurate infusion, adjusted by its baseline value

Time frame:
8 weeks after randomization
Reported as:
Least squares mean · (mmHg)
Baseline-adjusted Glomerular Hydrostatic Pressure at 8 Weeks After Randomization
(mmHg)FenofibratePlacebo
Baseline-adjusted Glomerular Hydrostatic Pressure at 8 Weeks After Randomization11.1 (10.6 to 11.6)12.1 (11.7 to 12.6)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.0046 · Mean difference (net): -1.05 · 95% CI -1.7 to -0.4
SecondaryBaseline-adjusted Glomerular Filtration Pressure at 8 Weeks After Randomization

Glomerular filtration pressure (mmHg) measured by means of para-aminohippurate infusion, adjusted by its baseline value

Time frame:
8 weeks after randomization
Reported as:
Least squares mean · mmHg
Baseline-adjusted Glomerular Filtration Pressure at 8 Weeks After Randomization
mmHgFenofibratePlacebo
Baseline-adjusted Glomerular Filtration Pressure at 8 Weeks After Randomization46.6 (46.0 to 47.2)48.0 (47.4 to 48.7)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.0027 · Mean difference (net): -1.4 · 95% CI -2.3 to -0.6
SecondaryBaseline-adjusted eGFR-SCr at the End of the Wash-out Period

GFR estimated from serum creatinine (ml/min/1.73 m2) using the CKD-EPI equation, adjusted by its baseline value

Time frame:
84 weeks after randomization
Reported as:
Least squares mean · ml/min/1.73m2
Baseline-adjusted eGFR-SCr at the End of the Wash-out Period
ml/min/1.73m2FenofibratePlacebo
Baseline-adjusted eGFR-SCr at the End of the Wash-out Period69.4 (63.1 to 75.7)69.9 (64.2 to 75.7)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.91 · Mean difference (net): -0.51 · 95% CI -9.0 to 7.9
SecondaryBaseline-adjusted eGFR-CysC at the End of the Wash-out Period

GFR estimated from serum cystatin C (ml/min/1.73 m2) using the CKD-EPI equation, adjusted by its baseline value

Time frame:
84 weeks after randomization
Reported as:
Least squares mean · ml/min/1.73m2
Baseline-adjusted eGFR-CysC at the End of the Wash-out Period
ml/min/1.73m2FenofibratePlacebo
Baseline-adjusted eGFR-CysC at the End of the Wash-out Period59.2 (53.2 to 65.1)58.2 (52.9 to 63.6)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.82 · Mean difference (net): 0.93 · 95% CI -7.1 to 9.0
SecondaryBaseline-adjusted uAER at the End of the Wash-out Period

Urinary albumin excretion rate (uAER, μg/min) based on overnight urine collection, adjusted by its baseline value

Time frame:
84 weeks after randomization
Reported as:
Geometric least squares mean · μg/min
Baseline-adjusted uAER at the End of the Wash-out Period
μg/minFenofibratePlacebo
Baseline-adjusted uAER at the End of the Wash-out Period110.5 (52.3 to 233.1)103.5 (52.0 to 206.1)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.90 · Uaer fenofibrate to placebo ratio: 1.07 · 95% CI 0.4 to 3.0
SecondaryBaseline-adjusted iGFR at the End of Treatment

GFR measured by iohexol plasma disappearance (ml/min/1.73 m2), adjusted by its baseline value

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · ml/min /1.73 m2
Baseline-adjusted iGFR at the End of Treatment
ml/min /1.73 m2FenofibratePlacebo
Baseline-adjusted iGFR at the End of Treatment56.6 (51.0 to 62.2)61.9 (56.8 to 66.9)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.16 · Mean difference (net): -5.3 · 95% CI -12.2 to 1.7
SecondaryBaseline-adjusted eGFR-SCr at the End of Treatment

GFR estimated from serum creatinine (ml/min/1.73 m2) using the CKD-EPI equation, adjusted by its baseline value

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · ml/min/1.73m2
Baseline-adjusted eGFR-SCr at the End of Treatment
ml/min/1.73m2FenofibratePlacebo
Baseline-adjusted eGFR-SCr at the End of Treatment56.2 (49.4 to 63.0)67.9 (62.0 to 73.8)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.017 · Mean difference (net): -11.7 · 95% CI -20.5 to -2.9
SecondaryBaseline-adjusted eGFR-CysC at the End of Treatment

GFR estimated from serum cystatin C (ml/min/1.73 m2) using the CKD-EPI equation, adjusted by its baseline value

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · ml/min/1.73m2
Baseline-adjusted eGFR-CysC at the End of Treatment
ml/min/1.73m2FenofibratePlacebo
Baseline-adjusted eGFR-CysC at the End of Treatment53.7 (47.1 to 60.2)58.0 (52.5 to 63.6)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.32 · Mean difference (net): -4.4 · 95% CI -12.8 to 4.0
SecondaryBaseline-adjusted uAER at the End of Treatment

Urinary albumin excretion rate (uAER, μg/min) based on overnight urine collection, adjusted by its baseline value

Time frame:
76 weeks after randomization
Reported as:
Geometric least squares mean · μg/min
Baseline-adjusted uAER at the End of Treatment
μg/minFenofibratePlacebo
Baseline-adjusted uAER at the End of Treatment83.2 (40.7 to 170.4)131.4 (68.1 to 253.5)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.37 · Aer fenofibrate to pacebo ratio: 0.63 · 95% CI 0.2 to 1.7
SecondaryWeek 8-adjusted iGFR at the End of Treatment

GFR measured by iohexol plasma disappearance (ml/min/1.73 m2), adjusted by its value at week 8

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · ml/min/1.73m2
Week 8-adjusted iGFR at the End of Treatment
ml/min/1.73m2FenofibratePlacebo
Week 8-adjusted iGFR at the End of Treatment61.3 (56.0 to 66.7)59.9 (55.3 to 64.5)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.68 · Mean difference (net): 1.4 · 95% CI -5.1 to 8.0
SecondaryWeek 8-adjusted eGFR-SCr at the End of Treatment

GFR estimated from serum creatine (ml/min/1.73 m2) using the CKD-EPI equation, adjusted by its value at week 8

Time frame:
76 weeks from randomization
Reported as:
Least squares mean · ml/min/1.73m2
Week 8-adjusted eGFR-SCr at the End of Treatment
ml/min/1.73m2FenofibratePlacebo
Week 8-adjusted eGFR-SCr at the End of Treatment61.6 (56.0 to 67.1)64.6 (59.9 to 69.2)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.42 · Mean difference (net): -3.0 · 95% CI -10.2 to 4.2
SecondaryWeek 8-adjusted eGFR-CysC at the End of Treatment

GFR estimated from serum cystatin C (ml/min/1.73 m2) using the CKD-EPI equation, adjusted by its value at week 8

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · ml/min/1.73m2
Week 8-adjusted eGFR-CysC at the End of Treatment
ml/min/1.73m2FenofibratePlacebo
Week 8-adjusted eGFR-CysC at the End of Treatment56.5 (49.1 to 63.8)57.1 (51.0 to 63.2)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.89 · Mean difference (net): -0.7 · 95% CI -10.1 to 8.7
SecondaryWeek 8-adjusted uAER at the End of Treatment

Urinary Albumin excretion rate (uAER, μg/min) based on overnight urine collection, adjusted by its value at week 8

Time frame:
76 weeks after randomization
Reported as:
Geometric least squares mean · μg/min
Week 8-adjusted uAER at the End of Treatment
μg/minFenofibratePlacebo
Week 8-adjusted uAER at the End of Treatment110.3 (55.5 to 219.1)111.3 (59.8 to 207.2)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.98 · Aer fenofibrate to pacebo ratio: 0.99 · 95% CI 0.4 to 2.5
SecondaryeGFR-SCr Trajectory

Trajectory of GFR estimated from serum creatinine (ml/min/1.73 m2/year) using the CKD-EPI equation

Time frame:
8 to 76 weeks from randomization
Reported as:
Least squares mean · ml/min/1.73m2/year
eGFR-SCr Trajectory
ml/min/1.73m2/yearFenofibratePlacebo
eGFR-SCr Trajectory-3.6 (-8.4 to 1.2)-3.6 (-6.8 to -0.5)
Statistical analysis
  • Fenofibrate vs Placebo · Mixed Models Analysis · p = 0.99 · Mean difference (net): 0.0 · 95% CI -5.6 to 5.6
SecondaryeGFR-SCys Trajectory

Trajectory of GFR estimated from serum cystatin C (ml/min/1.73 m2/year) using the CKD-EPI equation

Time frame:
8 to 76 weeks from randomization
Reported as:
Least squares mean · ml/min/1.73m2/year
eGFR-SCys Trajectory
ml/min/1.73m2/yearFenofibratePlacebo
eGFR-SCys Trajectory-3.3 (-7.7 to 1.2)-3.8 (-8.0 to 0.6)
Statistical analysis
  • Fenofibrate vs Placebo · Mixed Models Analysis · p = 0.84 · Mean difference (net): 0.65 · 95% CI -5.5 to 6.8
PrimaryBaseline-adjusted Serum Levels of CD160 at the End of the Drug-wash-out Period (Week 84).

CD160 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
84 weeks after randomization
Reported as:
Least squares mean · pg/ml
Baseline-adjusted Serum Levels of CD160 at the End of the Drug-wash-out Period (Week 84).
pg/mlFenofibratePlacebo
Baseline-adjusted Serum Levels of CD160 at the End of the Drug-wash-out Period (Week 84).82.4 (70.6 to 94.2)85.0 (74.3 to 95.6)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.76 · Mean difference (net): -2.6 · 95% CI -18.7 to 13.5
PrimaryBaseline-adjusted Serum Levels of CD27 at the End of the Drug-wash-out Period (Week 84).

CD27 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
84 weeks from randomization
Reported as:
Least squares mean · pg/ml
Baseline-adjusted Serum Levels of CD27 at the End of the Drug-wash-out Period (Week 84).
pg/mlFenofibratePlacebo
Baseline-adjusted Serum Levels of CD27 at the End of the Drug-wash-out Period (Week 84).163.2 (138.4 to 188.1)168.4 (146.3 to 190.5)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.77 · Mean difference (net): -5.2 · 95% CI -39.1 to 28.7
PrimaryBaseline-adjusted Serum Levels of DLL1 at the End of the Drug-wash-out Period (Week 84).

DLL1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
84 weeks from randomization
Reported as:
Least squares mean · pg/ml
Baseline-adjusted Serum Levels of DLL1 at the End of the Drug-wash-out Period (Week 84).
pg/mlFenofibratePlacebo
Baseline-adjusted Serum Levels of DLL1 at the End of the Drug-wash-out Period (Week 84).1511.0 (1347.8 to 1674.2)1592.9 (1445.9 to 1739.9)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.47 · Mean difference (net): -81.9 · 95% CI -301.3 to 137.5
PrimaryBaseline-adjusted Serum Levels of EDA2R at the End of the Drug-wash-out Period (Week 84).

EDA2R is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
84 weeks from randomization
Reported as:
Least squares mean · pg/ml
Baseline-adjusted Serum Levels of EDA2R at the End of the Drug-wash-out Period (Week 84).
pg/mlFenofibratePlacebo
Baseline-adjusted Serum Levels of EDA2R at the End of the Drug-wash-out Period (Week 84).14.8 (12.4 to 17.2)14.8 (12.6 to 17.0)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.99 · Mean difference (net): 0.0 · 95% CI -3.2 to 3.2
PrimaryBaseline-adjusted Serum Levels of EFNA4 at the End of the Drug-wash-out Period (Week 84).

EFNA4 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
84 weeks from randomization
Reported as:
Least squares mean · pg/ml
Baseline-adjusted Serum Levels of EFNA4 at the End of the Drug-wash-out Period (Week 84).
pg/mlFenofibratePlacebo
Baseline-adjusted Serum Levels of EFNA4 at the End of the Drug-wash-out Period (Week 84).95.5 (83.1 to 107.9)88.2 (77.3 to 99.1)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.42 · Mean difference (net): 7.3 · 95% CI -9.9 to 24.6
PrimaryBaseline-adjusted Serum Levels of EPHA2 at the End of the Drug-wash-out Period (Week 84).

EPHA2 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
84 weeks from randomization
Reported as:
Least squares mean · pg/ml
Baseline-adjusted Serum Levels of EPHA2 at the End of the Drug-wash-out Period (Week 84).
pg/mlFenofibratePlacebo
Baseline-adjusted Serum Levels of EPHA2 at the End of the Drug-wash-out Period (Week 84).19.9 (16.4 to 23.3)19.3 (16.1 to 22.5)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.81 · Mean difference (net): 0.6 · 95% CI -4.1 to 5.2
PrimaryBaseline-adjusted Serum Levels of GFR-alpha-1 at the End of the Drug-wash-out Period (Week 84).

GFR-alpha-1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
84 weeks from randomization
Reported as:
Least squares mean · pg/ml
Baseline-adjusted Serum Levels of GFR-alpha-1 at the End of the Drug-wash-out Period (Week 84).
pg/mlFenofibratePlacebo
Baseline-adjusted Serum Levels of GFR-alpha-1 at the End of the Drug-wash-out Period (Week 84).770.6 (662.1 to 879.2)819.1 (721.0 to 917.3)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.52 · Mean difference (net): -48.5 · 95% CI -193.6 to 96.6
PrimaryBaseline-adjusted Serum Levels of IL-1RT1 at the End of the Drug-wash-out Period (Week 84).

IL-1RT1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
84 weeks from randomization
Reported as:
Least squares mean · pg/ml
Baseline-adjusted Serum Levels of IL-1RT1 at the End of the Drug-wash-out Period (Week 84).
pg/mlFenofibratePlacebo
Baseline-adjusted Serum Levels of IL-1RT1 at the End of the Drug-wash-out Period (Week 84).157.7 (134.9 to 180.5)174.4 (153.6 to 195.1)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.30 · Mean difference (net): -16.6 · 95% CI -47.5 to 14.2
PrimaryBaseline-adjusted Serum Levels of KIM1 at the End of the Drug-wash-out Period (Week 84).

KIM1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
84 weeks from randomization
Reported as:
Least squares mean · pg/ml
Baseline-adjusted Serum Levels of KIM1 at the End of the Drug-wash-out Period (Week 84).
pg/mlFenofibratePlacebo
Baseline-adjusted Serum Levels of KIM1 at the End of the Drug-wash-out Period (Week 84).342.7 (229.3 to 456.1)280.4 (176.3 to 384.6)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.45 · Mean difference (net): 62.2 · 95% CI -94.2 to 218.7
PrimaryBaseline-adjusted Serum Levels of LAYN at the End of the Drug-wash-out Period (Week 84).

LAYN is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
84 weeks from randomization
Reported as:
Least squares mean · pg/ml
Baseline-adjusted Serum Levels of LAYN at the End of the Drug-wash-out Period (Week 84).
pg/mlFenofibratePlacebo
Baseline-adjusted Serum Levels of LAYN at the End of the Drug-wash-out Period (Week 84).6.6 (5.3 to 7.8)6.5 (5.3 to 7.7)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.93 · Mean difference (net): 0.1 · 95% CI -1.7 to 1.8
PrimaryBaseline-adjusted Serum Levels of LTBR at the End of the Drug-wash-out Period (Week 84).

LTBR is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
84 weeks from randomization
Reported as:
Least squares mean · pg/ml
Baseline-adjusted Serum Levels of LTBR at the End of the Drug-wash-out Period (Week 84).
pg/mlFenofibratePlacebo
Baseline-adjusted Serum Levels of LTBR at the End of the Drug-wash-out Period (Week 84).146.7 (121.7 to 171.6)157.6 (134.8 to 180.4)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.53 · Mean difference (net): -11.0 · 95% CI -44.4 to 22.5
PrimaryBaseline-adjusted Serum Levels of PI3 at the End of the Drug-wash-out Period (Week 84).

PI3 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
84 weeks from randomization
Reported as:
Least squares mean · pg/ml
Baseline-adjusted Serum Levels of PI3 at the End of the Drug-wash-out Period (Week 84).
pg/mlFenofibratePlacebo
Baseline-adjusted Serum Levels of PI3 at the End of the Drug-wash-out Period (Week 84).14955.3 (12287.5 to 17623.0)13971.7 (11557.3 to 16396.1)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.60 · Mean difference (net): 983.6 · 95% CI -2661.4 to 4628.5
PrimaryBaseline-adjusted Serum Levels of PVRL4 at the End of the Drug-wash-out Period (Week 84).

PVRL4 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
84 weeks from randomization
Reported as:
Least squares mean · pg/ml
Baseline-adjusted Serum Levels of PVRL4 at the End of the Drug-wash-out Period (Week 84).
pg/mlFenofibratePlacebo
Baseline-adjusted Serum Levels of PVRL4 at the End of the Drug-wash-out Period (Week 84).106.5 (93.8 to 119.2)119.2 (107.4 to 130.5)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.17 · Mean difference (net): -12.5 · 95% CI -29.5 to 4.6
PrimaryBaseline-adjusted Serum Levels of RELT at the End of the Drug-wash-out Period (Week 84).

RELT is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
84 weeks from randomization
Reported as:
Least squares mean · pg/ml
Baseline-adjusted Serum Levels of RELT at the End of the Drug-wash-out Period (Week 84).
pg/mlFenofibratePlacebo
Baseline-adjusted Serum Levels of RELT at the End of the Drug-wash-out Period (Week 84).940.7 (803.6 to 1077.8)897.7 (774.4 to 1021.0)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.67 · Mean difference (net): 43.0 · 95% CI -148.8 to 234.8
PrimaryBaseline-adjusted Serum Levels of SYND1 at the End of the Drug-wash-out Period (Week 84).

SYND1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
84 weeks from randomization
Reported as:
Least squares mean · pg/ml
Baseline-adjusted Serum Levels of SYND1 at the End of the Drug-wash-out Period (Week 84).
pg/mlFenofibratePlacebo
Baseline-adjusted Serum Levels of SYND1 at the End of the Drug-wash-out Period (Week 84).213.2 (186.6 to 239.9)216.4 (192.2 to 240.7)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.96 · Mean difference (net): -3.2 · 95% CI -38.8 to 32.4
PrimaryBaseline-adjusted Serum Levels of TNFR1 at the End of the Drug-wash-out Period (Week 84).

TNFR1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml

Time frame:
84 weeks from randomization
Reported as:
Least squares mean · pg/ml
Baseline-adjusted Serum Levels of TNFR1 at the End of the Drug-wash-out Period (Week 84).
pg/mlFenofibratePlacebo
Baseline-adjusted Serum Levels of TNFR1 at the End of the Drug-wash-out Period (Week 84).8997.9 (7846.6 to 10149.3)9673.4 (8651.3 to 10695.5)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.40 · Mean difference (net): -675.5 · 95% CI -2224.6 to 873.7
PrimaryBaseline-adjusted Serum Levels of TNFR2 at the End of the Drug-wash-out Period (Week 84).

TNFR2 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml

Time frame:
84 weeks from randomization
Reported as:
Least squares mean · pg/ml
Baseline-adjusted Serum Levels of TNFR2 at the End of the Drug-wash-out Period (Week 84).
pg/mlFenofibratePlacebo
Baseline-adjusted Serum Levels of TNFR2 at the End of the Drug-wash-out Period (Week 84).8863.6 (7547.4 to 10179.8)8963.4 (7803.7 to 10123.2)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.91 · Mean difference (net): -99.8 · 95% CI -1887.7 to 1688.0
PrimaryBaseline-adjusted Serum Levels of TNFRSF10A at the End of the Drug-wash-out Period (Week 84).

TNFRSF10A is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
84 weeks from randomization
Reported as:
Least squares mean · pg/ml
Baseline-adjusted Serum Levels of TNFRSF10A at the End of the Drug-wash-out Period (Week 84).
pg/mlFenofibratePlacebo
Baseline-adjusted Serum Levels of TNFRSF10A at the End of the Drug-wash-out Period (Week 84).18.8 (15 to 22.6)21.1 (17.6 to 24.5)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.40 · Mean difference (net): -2.3 · 95% CI -7.4 to 2.9
PrimaryBaseline-adjusted Serum Levels of TNFRSF4 at the End of the Drug-wash-out Period (Week 84).

TNFRSF4 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
84 weeks from randomization
Reported as:
Least squares mean · pg/ml
Baseline-adjusted Serum Levels of TNFRSF4 at the End of the Drug-wash-out Period (Week 84).
pg/mlFenofibratePlacebo
Baseline-adjusted Serum Levels of TNFRSF4 at the End of the Drug-wash-out Period (Week 84).9.7 (7.7 to 11.8)10.1 (8.3 to 12.0)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.77 · Mean difference (net): -0.4 · 95% CI -3.2 to 2.4
PrimaryBaseline-adjusted Serum Levels of TNFRSF6B at the End of the Drug-wash-out Period (Week 84).

TNFRSF6B is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
84 weeks from randomization
Reported as:
Least squares mean · pg/ml
Baseline-adjusted Serum Levels of TNFRSF6B at the End of the Drug-wash-out Period (Week 84).
pg/mlFenofibratePlacebo
Baseline-adjusted Serum Levels of TNFRSF6B at the End of the Drug-wash-out Period (Week 84).124.2 (106.3 to 142)132.2 (117.1 to 147.3)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.51 · Mean difference (net): -8.0 · 95% CI -31.6 to 15.6
PrimaryBaseline-adjusted Serum Levels of WFDC2 at the End of the Drug-wash-out Period (Week 84).

WFDC2 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
84 weeks from randomization
Reported as:
Least squares mean · pg/ml
Baseline-adjusted Serum Levels of WFDC2 at the End of the Drug-wash-out Period (Week 84).
pg/mlFenofibratePlacebo
Baseline-adjusted Serum Levels of WFDC2 at the End of the Drug-wash-out Period (Week 84).286.5 (231.0 to 341.9)262.0 (210.9 to 313.0)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.53 · Mean difference (net): 24.5 · 95% CI -50.2 to 99.2
SecondaryBaseline-adjusted Serum Levels of CD160 at the End of the Treatment Period (Week 76).

CD160 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · pg/ml
Baseline-adjusted Serum Levels of CD160 at the End of the Treatment Period (Week 76).
pg/mlFenofibratePlacebo
Baseline-adjusted Serum Levels of CD160 at the End of the Treatment Period (Week 76).87.1 (75.7 to 98.5)79.8 (69.6 to 90.1)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.37 · Mean difference (net): 7.3 · 95% CI -8.3 to 22.9
SecondaryBaseline-adjusted Serum Levels of CD27 at the End of the Treatment Period (Week 76).

CD27 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · pg/ml
Baseline-adjusted Serum Levels of CD27 at the End of the Treatment Period (Week 76).
pg/mlFenofibratePlacebo
Baseline-adjusted Serum Levels of CD27 at the End of the Treatment Period (Week 76).163.0 (137.1 to 188.8)165.1 (142.1 to 188.2)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.91 · Mean difference (net): -2.2 · 95% CI -37.5 to 33.2
SecondaryBaseline-adjusted Serum Levels of DLL1 at the End of the Treatment Period (Week 76).

DLL1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · pg/ml
Baseline-adjusted Serum Levels of DLL1 at the End of the Treatment Period (Week 76).
pg/mlFenofibratePlacebo
Baseline-adjusted Serum Levels of DLL1 at the End of the Treatment Period (Week 76).1597.0 (1363.3 to 1830.7)1567.4 (1356.9 to 1777.9)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.86 · Mean difference (net): 29.6 · 95% CI -284.6 to 343.8
SecondaryBaseline-adjusted Serum Levels of EDA2R at the End of the Treatment Period (Week 76).

EDA2R is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · pg/ml
Baseline-adjusted Serum Levels of EDA2R at the End of the Treatment Period (Week 76).
pg/mlFenofibratePlacebo
Baseline-adjusted Serum Levels of EDA2R at the End of the Treatment Period (Week 76).16.0 (13.8 to 18.3)14.3 (12.3 to 16.4)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.29 · Mean difference (net): 1.7 · 95% CI -1.4 to 4.7
SecondaryBaseline-adjusted Serum Levels of EFNA4 at the End of the Treatment Period (Week 76).

EFNA4 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · pg/ml
Baseline-adjusted Serum Levels of EFNA4 at the End of the Treatment Period (Week 76).
pg/mlFenofibratePlacebo
Baseline-adjusted Serum Levels of EFNA4 at the End of the Treatment Period (Week 76).92.6 (81.8 to 103.5)81.8 (72.3 to 91.3)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.18 · Mean difference (net): 10.8 · 95% CI -4.2 to 25.9
SecondaryBaseline-adjusted Serum Levels of EPHA2 at the End of the Treatment Period (Week 76).

EPHA2 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · pg/ml
Baseline-adjusted Serum Levels of EPHA2 at the End of the Treatment Period (Week 76).
pg/mlFenofibratePlacebo
Baseline-adjusted Serum Levels of EPHA2 at the End of the Treatment Period (Week 76).17.1 (-15.1 to 49.3)36.2 (6.5 to 65.8)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.40 · Mean difference (net): -19.1 · 95% CI -62.4 to 24.2
SecondaryBaseline-adjusted Serum Levels of GFR-alpha-1 at the End of the Treatment Period (Week 76).

GFR-alpha-1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · pg/ml
Baseline-adjusted Serum Levels of GFR-alpha-1 at the End of the Treatment Period (Week 76).
pg/mlFenofibratePlacebo
Baseline-adjusted Serum Levels of GFR-alpha-1 at the End of the Treatment Period (Week 76).853.8 (724.1 to 983.5)771.1 (653.8 to 888.4)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.36 · Median difference (net): 82.7 · 95% CI -90.7 to 256.1
SecondaryBaseline-adjusted Serum Levels of IL-1RT1 at the End of the Treatment Period (Week 76).

IL-1RT1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · pg/ml
Baseline-adjusted Serum Levels of IL-1RT1 at the End of the Treatment Period (Week 76).
pg/mlFenofibratePlacebo
Baseline-adjusted Serum Levels of IL-1RT1 at the End of the Treatment Period (Week 76).157.2 (134.0 to 180.4)165.7 (144.6 to 186.8)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.60 · Mean difference (net): -8.5 · 95% CI -39.9 to 22.9
SecondaryBaseline-adjusted Serum Levels of KIM1 at the End of the Treatment Period (Week 76).

KIM1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · pg/ml
Baseline-adjusted Serum Levels of KIM1 at the End of the Treatment Period (Week 76).
pg/mlFenofibratePlacebo
Baseline-adjusted Serum Levels of KIM1 at the End of the Treatment Period (Week 76).330.1 (212.3 to 447.9)299.9 (191.7 to 408.0)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.72 · Mean difference (net): 30.2 · 95% CI -132.3 to 192.8
SecondaryBaseline-adjusted Serum Levels of LAYN at the End of the Treatment Period (Week 76).

LAYN is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · pg/ml
Baseline-adjusted Serum Levels of LAYN at the End of the Treatment Period (Week 76).
pg/mlFenofibratePlacebo
Baseline-adjusted Serum Levels of LAYN at the End of the Treatment Period (Week 76).6.7 (5.5 to 7.9)6.5 (5.4 to 7.6)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.83 · Mean difference (net): 0.2 · 95% CI -1.4 to 1.8
SecondaryBaseline-adjusted Serum Levels of LTBR at the End of the Treatment Period (Week 76).

LTBR is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · pg/ml
Baseline-adjusted Serum Levels of LTBR at the End of the Treatment Period (Week 76).
pg/mlFenofibratePlacebo
Baseline-adjusted Serum Levels of LTBR at the End of the Treatment Period (Week 76).154.8 (132.7 to 176.8)150.8 (130.7 to 171.0)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.80 · Mean difference (net): 3.9 · 95% CI -25.6 to 33.5
SecondaryBaseline-adjusted Serum Levels of PI3 at the End of the Treatment Period (Week 76).

PI3 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · pg/ml
Baseline-adjusted Serum Levels of PI3 at the End of the Treatment Period (Week 76).
pg/mlFenofibratePlacebo
Baseline-adjusted Serum Levels of PI3 at the End of the Treatment Period (Week 76).16915.1 (14338.3 to 19492.0)12726.1 (10393.9 to 15058.2)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.03 · Mean difference (net): 4189.1 · 95% CI 668.3 to 7709.8
SecondaryBaseline-adjusted Serum Levels of PVRL4 at the End of the Treatment Period (Week 76).

PVRL4 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · pg/ml
Baseline-adjusted Serum Levels of PVRL4 at the End of the Treatment Period (Week 76).
pg/mlFenofibratePlacebo
Baseline-adjusted Serum Levels of PVRL4 at the End of the Treatment Period (Week 76).110.2 (95.3 to 125.1)118.6 (105.1 to 132.1)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.42 · Mean difference (net): -8.4 · 95% CI -28.3 to 11.6
SecondaryBaseline-adjusted Serum Levels of RELT at the End of the Treatment Period (Week 76).

RELT is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · pg/ml
Baseline-adjusted Serum Levels of RELT at the End of the Treatment Period (Week 76).
pg/mlFenofibratePlacebo
Baseline-adjusted Serum Levels of RELT at the End of the Treatment Period (Week 76).935.5 (799.6 to 1071.4)876.2 (754.0 to 998.4)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.55 · Mean difference (net): 59.3 · 95% CI -130.8 to 249.4
SecondaryBaseline-adjusted Serum Levels of SYND1 at the End of the Treatment Period (Week 76).

SYND1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · pg/ml
Baseline-adjusted Serum Levels of SYND1 at the End of the Treatment Period (Week 76).
pg/mlFenofibratePlacebo
Baseline-adjusted Serum Levels of SYND1 at the End of the Treatment Period (Week 76).196.0 (163.1 to 229.0)203.2 (173.2 to 233.2)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.75 · Mean difference (net): -7.2 · 95% CI -51.2 to 36.8
SecondaryBaseline-adjusted Serum Levels of TNFR1 at the End of the Treatment Period (Week 76).

TNFR1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · pg/ml
Baseline-adjusted Serum Levels of TNFR1 at the End of the Treatment Period (Week 76).
pg/mlFenofibratePlacebo
Baseline-adjusted Serum Levels of TNFR1 at the End of the Treatment Period (Week 76).9539.0 (8433.1 to 10644.9)9576.4 (8594.6 to 10558.2)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.96 · Mean difference (net): -37.4 · 95% CI -1525.4 to 1450.6
SecondaryBaseline-adjusted Serum Levels of TNFR2 at the End of the Treatment Period (Week 76).

TNFR2 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · pg/ml
Baseline-adjusted Serum Levels of TNFR2 at the End of the Treatment Period (Week 76).
pg/mlFenofibratePlacebo
Baseline-adjusted Serum Levels of TNFR2 at the End of the Treatment Period (Week 76).10126.1 (8202.2 to 12050.0)8880.8 (7185.6 to 10576.0)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.36 · Mean difference (net): 1245.3 · 95% CI -1368.0 to 3858.5
SecondaryBaseline-adjusted Serum Levels of TNFRSF10A at the End of the Treatment Period (Week 76).

TNFRSF10A is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · pg/ml
Baseline-adjusted Serum Levels of TNFRSF10A at the End of the Treatment Period (Week 76).
pg/mlFenofibratePlacebo
Baseline-adjusted Serum Levels of TNFRSF10A at the End of the Treatment Period (Week 76).20.1 (16.7 to 23.6)20.9 (17.8 to 24.1)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.74 · Mean difference (net): -0.8 · 95% CI -5.5 to 3.9
SecondaryBaseline-adjusted Serum Levels of TNFRSF4 at the End of the Treatment Period (Week 76).

TNFRSF4 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · pg/ml
Baseline-adjusted Serum Levels of TNFRSF4 at the End of the Treatment Period (Week 76).
pg/mlFenofibratePlacebo
Baseline-adjusted Serum Levels of TNFRSF4 at the End of the Treatment Period (Week 76).9.6 (8.1 to 11.1)9.9 (8.5 to 11.3)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.77 · Mean difference (net): -0.3 · 95% CI -2.4 to 1.7
SecondaryBaseline-adjusted Serum Levels of TNFRSF6B at the End of the Treatment Period (Week 76).

TNFRSF6B is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · pg/ml
Baseline-adjusted Serum Levels of TNFRSF6B at the End of the Treatment Period (Week 76).
pg/mlFenofibratePlacebo
Baseline-adjusted Serum Levels of TNFRSF6B at the End of the Treatment Period (Week 76).122.3 (96.6 to 148.1)134.4 (112.6 to 156.3)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.50 · Mean difference (net): -0.3 · 95% CI -2.4 to 1.7
SecondaryBaseline-adjusted Serum Levels of WFDC2 at the End of the Treatment Period (Week 76).

WFDC2 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · pg/ml
Baseline-adjusted Serum Levels of WFDC2 at the End of the Treatment Period (Week 76).
pg/mlFenofibratePlacebo
Baseline-adjusted Serum Levels of WFDC2 at the End of the Treatment Period (Week 76).295.0 (237.9 to 352.2)258.3 (205.7 to 310.9)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.36 · Mean difference (net): 36.7 · 95% CI -40.2 to 113.7
SecondaryWeek 8-adjusted Serum Levels of CD160 at the End of the Treatment Period (Week 76).

CD160 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · pg/ml
Week 8-adjusted Serum Levels of CD160 at the End of the Treatment Period (Week 76).
pg/mlFenofibratePlacebo
Week 8-adjusted Serum Levels of CD160 at the End of the Treatment Period (Week 76).87.1 (77.7 to 96.5)80.4 (71.9 to 89.0)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.32 · Mean difference (net): 6.65 · 95% CI -6.2 to 19.5
SecondaryWeek 8-adjusted Serum Levels of CD27 at the End of the Treatment Period (Week 76).

CD27 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · pg/ml
Week 8-adjusted Serum Levels of CD27 at the End of the Treatment Period (Week 76).
pg/mlFenofibratePlacebo
Week 8-adjusted Serum Levels of CD27 at the End of the Treatment Period (Week 76).171.8 (149.9 to 193.7)161.8 (141.9 to 181.8)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.52 · Mean difference (net): 10.0 · 95% CI -19.7 to 39.6
SecondaryWeek 8-adjusted Serum Levels of DLL1 at the End of the Treatment Period (Week 76).

DLL1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · pg/ml
Week 8-adjusted Serum Levels of DLL1 at the End of the Treatment Period (Week 76).
pg/mlFenofibratePlacebo
Week 8-adjusted Serum Levels of DLL1 at the End of the Treatment Period (Week 76).1625.0 (1464.5 to 1785.6)1565.8 (1418.6 to 1713.0)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.60 · Mean difference (net): 59.3 · 95% CI -156.9 to 275.4
SecondaryWeek 8-adjusted Serum Levels of EDA2R at the End of the Treatment Period (Week 76).

EDA2R is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · pg/ml
Week 8-adjusted Serum Levels of EDA2R at the End of the Treatment Period (Week 76).
pg/mlFenofibratePlacebo
Week 8-adjusted Serum Levels of EDA2R at the End of the Treatment Period (Week 76).15.3 (13.5 to 17.2)14.9 (13.2 to 16.6)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.74 · Mean difference (net): 0.4 · 95% CI -2.1 to 3.0
SecondaryWeek 8-adjusted Serum Levels of EFNA4 at the End of the Treatment Period (Week 76).

EFNA4 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · pg/ml
Week 8-adjusted Serum Levels of EFNA4 at the End of the Treatment Period (Week 76).
pg/mlFenofibratePlacebo
Week 8-adjusted Serum Levels of EFNA4 at the End of the Treatment Period (Week 76).87.3 (79.9 to 94.7)85.7 (79.2 to 92.2)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.78 · Mean difference (net): 1.5 · 95% CI -9.0 to 12.0
SecondaryWeek 8-adjusted Serum Levels of EPHA2 at the End of the Treatment Period (Week 76).

EPHA2 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · pg/ml
Week 8-adjusted Serum Levels of EPHA2 at the End of the Treatment Period (Week 76).
pg/mlFenofibratePlacebo
Week 8-adjusted Serum Levels of EPHA2 at the End of the Treatment Period (Week 76).17.3 (-15.8 to 50.4)37.3 (7.0 to 67.7)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.39 · Mean difference (net): -20.0 · 95% CI -64.5 to 24.5
SecondaryWeek 8-adjusted Serum Levels of GFR-alpha-1 at the End of the Treatment Period (Week 76).

GFR-alpha-1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · pg/ml
Week 8-adjusted Serum Levels of GFR-alpha-1 at the End of the Treatment Period (Week 76).
pg/mlFenofibratePlacebo
Week 8-adjusted Serum Levels of GFR-alpha-1 at the End of the Treatment Period (Week 76).831.1 (728.7 to 933.5)792.8 (700.1 to 885.5)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.59 · Mean difference (net): 38.3 · 95% CI -100.2 to 176.9
SecondaryWeek 8-adjusted Serum Levels of IL-1RT1 at the End of the Treatment Period (Week 76).

IL-1RT1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · pg/ml
Week 8-adjusted Serum Levels of IL-1RT1 at the End of the Treatment Period (Week 76).
pg/mlFenofibratePlacebo
Week 8-adjusted Serum Levels of IL-1RT1 at the End of the Treatment Period (Week 76).156.9 (136.3 to 177.5)167.8 (148.9 to 186.7)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.46 · Mean difference (net): -10.9 · 95% CI -38.9 to 17.2
SecondaryWeek 8-adjusted Serum Levels of KIM1 at the End of the Treatment Period (Week 76).

KIM1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · pg/ml
Week 8-adjusted Serum Levels of KIM1 at the End of the Treatment Period (Week 76).
pg/mlFenofibratePlacebo
Week 8-adjusted Serum Levels of KIM1 at the End of the Treatment Period (Week 76).336.2 (224.6 to 447.9)295.6 (193.2 to 398.0)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.61 · Mean difference (net): 40.7 · 95% CI -113.6 to 194.9
SecondaryWeek 8-adjusted Serum Levels of LAYN at the End of the Treatment Period (Week 76).

LAYN is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · pg/ml
Week 8-adjusted Serum Levels of LAYN at the End of the Treatment Period (Week 76).
pg/mlFenofibratePlacebo
Week 8-adjusted Serum Levels of LAYN at the End of the Treatment Period (Week 76).6.3 (4.9 to 7.7)6.9 (5.6 to 8.2)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.57 · Mean difference (net): -0.6 · 95% CI -2.5 to 1.3
SecondaryWeek 8-adjusted Serum Levels of LTBR at the End of the Treatment Period (Week 76).

LTBR is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · pg/ml
Week 8-adjusted Serum Levels of LTBR at the End of the Treatment Period (Week 76).
pg/mlFenofibratePlacebo
Week 8-adjusted Serum Levels of LTBR at the End of the Treatment Period (Week 76).151.9 (137.6 to 166.2)156.6 (143.5 to 169.6)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.64 · Mean difference (net): -4.7 · 95% CI -24.0 to 14.6
SecondaryWeek 8-adjusted Serum Levels of PI3 at the End of the Treatment Period (Week 76).

PI3 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · pg/ml
Week 8-adjusted Serum Levels of PI3 at the End of the Treatment Period (Week 76).
pg/mlFenofibratePlacebo
Week 8-adjusted Serum Levels of PI3 at the End of the Treatment Period (Week 76).15392.1 (13080.7 to 17703.6)13728.7 (11692.5 to 15765.0)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.33 · Mean difference (net): 1663.4 · 95% CI -1577.9 to 4904.8
SecondaryWeek 8-adjusted Serum Levels of PVRL4 at the End of the Treatment Period (Week 76).

PVRL4 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · pg/ml
Week 8-adjusted Serum Levels of PVRL4 at the End of the Treatment Period (Week 76).
pg/mlFenofibratePlacebo
Week 8-adjusted Serum Levels of PVRL4 at the End of the Treatment Period (Week 76).111.7 (98.0 to 125.3)118.3 (105.8 to 130.8)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.49 · Mean difference (net): -6.7 · 95% CI -25.1 to 11.7
SecondaryWeek 8-adjusted Serum Levels of RELT at the End of the Treatment Period (Week 76).

RELT is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · pg/ml
Week 8-adjusted Serum Levels of RELT at the End of the Treatment Period (Week 76).
pg/mlFenofibratePlacebo
Week 8-adjusted Serum Levels of RELT at the End of the Treatment Period (Week 76).902.0 (800.2 to 1003.8)911.7 (819.0 to 1004.3)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.90 · Mean difference (net): -9.7 · 95% CI -154.6 to 135.3
SecondaryWeek 8-adjusted Serum Levels of SYND1 at the End of the Treatment Period (Week 76).

SYND1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · pg/ml
Week 8-adjusted Serum Levels of SYND1 at the End of the Treatment Period (Week 76).
pg/mlFenofibratePlacebo
Week 8-adjusted Serum Levels of SYND1 at the End of the Treatment Period (Week 76).192.6 (167.7 to 217.4)211.9 (189.3 to 234.5)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.27 · Mean difference (net): -19.3 · 95% CI -52.8 to 14.2
SecondaryWeek 8-adjusted Serum Levels of TNFR1 at the End of the Treatment Period (Week 76).

TNFR1 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · pg/ml
Week 8-adjusted Serum Levels of TNFR1 at the End of the Treatment Period (Week 76).
pg/mlFenofibratePlacebo
Week 8-adjusted Serum Levels of TNFR1 at the End of the Treatment Period (Week 76).9697.2 (8803.8 to 10590.6)9608.0 (8797.7 to 10418.3)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.89 · Mean difference (net): 89.1 · 95% CI -1118.5 to 1296.8
SecondaryWeek 8-adjusted Serum Levels of TNFR2 at the End of the Treatment Period (Week 76).

TNFR2 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · pg/ml
Week 8-adjusted Serum Levels of TNFR2 at the End of the Treatment Period (Week 76).
pg/mlFenofibratePlacebo
Week 8-adjusted Serum Levels of TNFR2 at the End of the Treatment Period (Week 76).10065.2 (8689.5 to 11440.9)9136.4 (7881.8 to 10391.0)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.35 · Mean difference (net): 928.8 · 95% CI -954.7 to 2812.3
SecondaryWeek 8-adjusted Serum Levels of TNFRSF10A at the End of the Treatment Period (Week 76).

TNFRSF10A is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · pg/ml
Week 8-adjusted Serum Levels of TNFRSF10A at the End of the Treatment Period (Week 76).
pg/mlFenofibratePlacebo
Week 8-adjusted Serum Levels of TNFRSF10A at the End of the Treatment Period (Week 76).20.9 (18.7 to 23.0)20.7 (18.7 to 22.6)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.92 · Mean difference (net): 0.2 · 95% CI -2.7 to 3.0
SecondaryWeek 8-adjusted Serum Levels of TNFRSF4 at the End of the Treatment Period (Week 76).

TNFRSF4 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · pg/ml
Week 8-adjusted Serum Levels of TNFRSF4 at the End of the Treatment Period (Week 76).
pg/mlFenofibratePlacebo
Week 8-adjusted Serum Levels of TNFRSF4 at the End of the Treatment Period (Week 76).9.9 (8.7 to 11.0)9.8 (8.7 to 10.8)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.91 · Mean difference (net): 0.1 · 95% CI -1.4 to 1.6
SecondaryWeek 8-adjusted Serum Levels of TNFRSF6B at the End of the Treatment Period (Week 76).

TNFRSF6B is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · pg/ml
Week 8-adjusted Serum Levels of TNFRSF6B at the End of the Treatment Period (Week 76).
pg/mlFenofibratePlacebo
Week 8-adjusted Serum Levels of TNFRSF6B at the End of the Treatment Period (Week 76).128.2 (108.0 to 148.3)131.8 (113.7 to 149.9)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.79 · Mean difference (net): -3.7 · 95% CI -30.5 to 90.6
SecondaryWeek 8-adjusted Serum Levels of WFDC2 at the End of the Treatment Period (Week 76).

WFDC2 is a serum protein included in the Joslin Kidney Panel (JKP) of biomarkers of kidney failure risk in diabetes. It is measured as pg/ml.

Time frame:
76 weeks after randomization
Reported as:
Least squares mean · pg/ml
Week 8-adjusted Serum Levels of WFDC2 at the End of the Treatment Period (Week 76).
pg/mlFenofibratePlacebo
Week 8-adjusted Serum Levels of WFDC2 at the End of the Treatment Period (Week 76).290.8 (243.8 to 337.8)263.4 (220.2 to 306.6)
Statistical analysis
  • Fenofibrate vs Placebo · ANCOVA · p = 0.41 · Mean difference (net): 27.4 · 95% CI -35.8 to 90.6

Adverse events

Collected over In each participant, adverse event data were collected from randomization to two months after the end of pharmacological treatment, or until study discontinuation for participants who did not complete the study. This corresponds to up to 84 weeks for participants who completed the study.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fenofibrate0/17 (0%)5/17 (29.4%)14/17 (82.4%)
Placebo0/18 (0%)7/18 (38.9%)14/18 (77.8%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventFenofibratePlacebo
Pain in extremityMusculoskeletal and connective tissue disorders0/172/18
DehydrationMetabolism and nutrition disorders1/171/18
DizzinessVascular disorders1/170/18
GastroenteritisInfections and infestations1/170/18
HypervolaemiaCardiac disorders1/170/18
HypotensionVascular disorders1/170/18
IridocyclitisEye disorders1/170/18
Oedema peripheralCardiac disorders1/170/18
PneumoniaRespiratory, thoracic and mediastinal disorders1/170/18
SyncopeVascular disorders1/170/18
Most frequent other events
Showing 10 of 43
Most frequent other events
EventFenofibratePlacebo
Laboratory test abnormalInvestigations11/178/18
Pain in extremityMusculoskeletal and connective tissue disorders1/173/18
DyspepsiaGastrointestinal disorders0/172/18
PneumoniaInfections and infestations1/172/18
RashSkin and subcutaneous tissue disorders1/172/18
Acute kidney injuryRenal and urinary disorders1/170/18
Back PainMusculoskeletal and connective tissue disorders1/170/18
ConstipationGastrointestinal disorders1/170/18
COVID-19Infections and infestations1/171/18
Eye haematomaEye disorders1/170/18

Baseline characteristics

Age, Continuous
Age, Continuous(Years)FenofibratePlaceboTotal
Mean53.8 ± 1353.3 ± 1353.5 ± 12.9
Sex: Female, Male
Sex: Female, Male(Participants)FenofibratePlaceboTotal
Female369
Male141226
Race (NIH/OMB)
Race (NIH/OMB)(Participants)FenofibratePlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American123
White161632
More than one race000
Unknown or Not Reported000
Diabetes duration
Diabetes duration(years)FenofibratePlaceboTotal
Mean40.0 ± 1345.1 ± 1342.6 ± 13.2
BMI
BMI(Kg/m2)FenofibratePlaceboTotal
Mean30.3 ± 4.731.5 ± 8.230.9 ± 6.6
HbA1c
HbA1c(%)FenofibratePlaceboTotal
Mean7.9 ± 1.87.4 ± 1.87.6 ± 1.8
SBP
SBP(mmHg)FenofibratePlaceboTotal
Mean128.3 ± 11131.6 ± 13130.0 ± 12
DBP
DBP(mmHg)FenofibratePlaceboTotal
Mean68.2 ± 867.5 ± 968.0 ± 9

3 further baseline measures are reported on the registry.

08

Study locations

4 sites
09

References and documents

Publications

  • Davis TM, Ting R, Best JD, Donoghoe MW, Drury PL, Sullivan DR, Jenkins AJ, O'Connell RL, Whiting MJ, Glasziou PP, Simes RJ, Kesaniemi YA, Gebski VJ, Scott RS, Keech AC; Fenofibrate Intervention and Event Lowering in Diabetes Study investigators. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia. 2011 Feb;54(2):280-90. doi: 10.1007/s00125-010-1951-1. Epub 2010 Nov 4. PubMed 21052978 ↗
  • Frazier R, Mehta R, Cai X, Lee J, Napoli S, Craven T, Tuazon J, Safdi A, Scialla J, Susztak K, Isakova T. Associations of Fenofibrate Therapy With Incidence and Progression of CKD in Patients With Type 2 Diabetes. Kidney Int Rep. 2018 Sep 18;4(1):94-102. doi: 10.1016/j.ekir.2018.09.006. eCollection 2019 Jan. PubMed 30596172 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Final research data will be formatted as a computerized dataset at the Joslin Diabetes Center. The final dataset will include both raw data and derived variables, which will be described in documents associated with the dataset. We will maintain the primary dataset for a minimum of 3 years following closeout of the grant as stipulated under the NIH Grants Policy Statement. In agreement with NIH's policy on the sharing of data from large, NIH-sponsored studies, the data collected in the course of the study will be archived in de-identified form in an NIH Central Repository for future distribution to the scientific community.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Data will be made available two years after completion of the study

Access criteria: Access will be governed by the NIDDK repository.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in May 2025, 39 months.

Results were first posted in Nov 2026, 1 year 6 months after primary completion.

Of 52 phase 2 interventional studies under Diabetic Nephropathies, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 31. This study's 39 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2021
First posted
Jun 18, 2021
StartActual
Jan 4, 2022
Primary completionActual
May 1, 2025
CompletionActual
Oct 15, 2026
Results first posted
Nov 10, 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 10, 2026
Results
Results posted
posted Nov 10, 2026
Study completion
Oct 31, 2026→Oct 15, 2026 (actual)
Nov 10, 2026
Enrollment
40 (estimated)→35 (actual)
Nov 10, 2026
Primary outcomes
3 edited, 20 added
What changed in the outcomes
  • EditedBaseline-adjusted iGFR at 8 weeks after randomizationWeeks After RandomizationTime frame: 8 weeks after randomization
  • EditedBaseline-adjusted iGFR at the endEnd of the drug washDrug Wash-out periodPeriodTime frame: 84 weeks after randomization
  • EditedBaseline-adjusted levelsSerum Levels of serum biomarkers of increased ESKD riskCD160 at the endEnd of the drug Drug-wash-out periodPeriod (Week 84).Time frame: 84 weeks after randomization
  • AddedBaseline-adjusted Serum Levels of CD27 at the End of the Drug-wash-out Period (Week 84).Time frame: 84 weeks from randomization
  • AddedBaseline-adjusted Serum Levels of DLL1 at the End of the Drug-wash-out Period (Week 84).Time frame: 84 weeks from randomization
  • AddedBaseline-adjusted Serum Levels of EDA2R at the End of the Drug-wash-out Period (Week 84).Time frame: 84 weeks from randomization
  • AddedBaseline-adjusted Serum Levels of EFNA4 at the End of the Drug-wash-out Period (Week 84).Time frame: 84 weeks from randomization
  • AddedBaseline-adjusted Serum Levels of EPHA2 at the End of the Drug-wash-out Period (Week 84).Time frame: 84 weeks from randomization
  • AddedBaseline-adjusted Serum Levels of GFR-alpha-1 at the End of the Drug-wash-out Period (Week 84).Time frame: 84 weeks from randomization
  • AddedBaseline-adjusted Serum Levels of IL-1RT1 at the End of the Drug-wash-out Period (Week 84).Time frame: 84 weeks from randomization
  • AddedBaseline-adjusted Serum Levels of KIM1 at the End of the Drug-wash-out Period (Week 84).Time frame: 84 weeks from randomization
  • AddedBaseline-adjusted Serum Levels of LAYN at the End of the Drug-wash-out Period (Week 84).Time frame: 84 weeks from randomization
  • AddedBaseline-adjusted Serum Levels of LTBR at the End of the Drug-wash-out Period (Week 84).Time frame: 84 weeks from randomization
  • AddedBaseline-adjusted Serum Levels of PI3 at the End of the Drug-wash-out Period (Week 84).Time frame: 84 weeks from randomization
  • AddedBaseline-adjusted Serum Levels of PVRL4 at the End of the Drug-wash-out Period (Week 84).Time frame: 84 weeks from randomization
  • AddedBaseline-adjusted Serum Levels of RELT at the End of the Drug-wash-out Period (Week 84).Time frame: 84 weeks from randomization
  • AddedBaseline-adjusted Serum Levels of SYND1 at the End of the Drug-wash-out Period (Week 84).Time frame: 84 weeks from randomization
  • AddedBaseline-adjusted Serum Levels of TNFR1 at the End of the Drug-wash-out Period (Week 84).Time frame: 84 weeks from randomization
  • AddedBaseline-adjusted Serum Levels of TNFR2 at the End of the Drug-wash-out Period (Week 84).Time frame: 84 weeks from randomization
  • AddedBaseline-adjusted Serum Levels of TNFRSF10A at the End of the Drug-wash-out Period (Week 84).Time frame: 84 weeks from randomization
  • AddedBaseline-adjusted Serum Levels of TNFRSF4 at the End of the Drug-wash-out Period (Week 84).Time frame: 84 weeks from randomization
  • AddedBaseline-adjusted Serum Levels of TNFRSF6B at the End of the Drug-wash-out Period (Week 84).Time frame: 84 weeks from randomization
  • AddedBaseline-adjusted Serum Levels of WFDC2 at the End of the Drug-wash-out Period (Week 84).Time frame: 84 weeks from randomization
Nov 10, 2026
Documents
Secondary outcomes
22 edited, 8 added, 37 more
What changed in the outcomes
  • EditedBaseline-adjusted iGFReGFR-SCr at the endEnd of treatmentthe Wash-out PeriodTime frame: 76 weeks after randomization → 84 weeks after randomization
  • EditedBaseline-adjusted iGFR at the endEnd of treatmentTreatmentTime frame: 76 weeks after randomization
  • EditedBaseline-adjusted eGFR-SCr at 8 weeks after randomizationWeeks After RandomizationTime frame: 8 weeks after randomization
  • EditedBaseline-adjusted eGFR-SCrCysC at the end of treatment8 Weeks After RandomizationTime frame: 76 weeks after randomization → 8 weeks after randomization
  • EditedBaseline-adjusted eGFR-SCrCysC at the endEnd of treatmentthe Wash-out PeriodTime frame: 76 weeks after randomization → 84 weeks after randomization
  • EditedBaseline-adjusted eGFR-SCruAER at the endEnd of the washWash-out periodPeriodTime frame: 84 weeks after randomization
  • EditedBaseline-adjusted eGFR-CysCuAER at 8 weeks after randomizationWeeks After RandomizationTime frame: 8 weeks after randomization
  • EditedBaseline-adjusted eGFR-CysCSCr at the endEnd of treatmentTreatmentTime frame: 76 weeks after randomization
  • EditedBaseline-adjusted eGFR-CysC at the endEnd of treatmentTreatmentTime frame: 76 weeks after randomization
  • EditedBaseline-adjusted eGFR-CysCuAER at the endEnd of the wash-out periodTreatmentTime frame: 84 weeks after randomization → 76 weeks after randomization
  • EditedBaseline-adjusted uAERCreatinine Clearance at 8 weeks after randomizationWeeks After RandomizationTime frame: 8 weeks after randomization
  • EditedBaselineWeek 8-adjusted uAERiGFR at the endEnd of treatmentTreatmentTime frame: 76 weeks after randomization
  • EditeduAERWeek 8-adjusted eGFR-SCr at the endEnd of treatmentTreatmentTime frame: 76 weeks after randomization → 76 weeks from randomization
  • EditedBaselineWeek 8-adjusted uAER at the endEnd of the wash-out periodTreatmentTime frame: 84 weeks after randomization → 76 weeks after randomization
  • EditedBaseline-adjusted creatinine clearanceERPF at 8 weeks after randomizationWeeks After RandomizationTime frame: 8 weeks after randomization
  • EditedBaseline-adjusted ERPFAfferent Renal Arteriolar Resistance at 8 weeks after randomizationWeeks After RandomizationTime frame: 8 weeks after randomization
  • EditedBaseline-adjusted afferent renal arteriolar resistanceEfferent Renal Arteriolar Resistance at 8 weeks after randomizationWeeks After RandomizationTime frame: 8 weeks after randomization
  • EditedBaseline-adjusted efferent renal arteriolar resistanceGlomerular Hydrostatic Pressure at 8 weeks after randomizationWeeks After RandomizationTime frame: 8 weeks after randomization
  • EditedBaseline-adjusted glomerular hydrostatic pressureGlomerular Filtration Pressure at 8 weeks after randomizationWeeks After RandomizationTime frame: 8 weeks after randomization
  • EditedeGFR-SCr trajectoryTrajectoryTime frame: 8 to 76 weeks from randomization
  • EditedeGFR-SCys trajectoryTrajectoryTime frame: 8 to 76 weeks from randomization
  • EditedBaselineWeek 8-adjusted levels of serum biomarkers of increased ESKD riskeGFR-CysC at the endEnd of treatmentTreatmentTime frame: 76 weeks after randomization
  • AddedBaseline-adjusted Serum Levels of CD160 at the End of the Treatment Period (Week 76).Time frame: 76 weeks after randomization
  • AddedBaseline-adjusted Serum Levels of CD27 at the End of the Treatment Period (Week 76).Time frame: 76 weeks after randomization
  • AddedBaseline-adjusted Serum Levels of DLL1 at the End of the Treatment Period (Week 76).Time frame: 76 weeks after randomization
  • AddedBaseline-adjusted Serum Levels of EDA2R at the End of the Treatment Period (Week 76).Time frame: 76 weeks after randomization
  • AddedBaseline-adjusted Serum Levels of EFNA4 at the End of the Treatment Period (Week 76).Time frame: 76 weeks after randomization
  • AddedBaseline-adjusted Serum Levels of EPHA2 at the End of the Treatment Period (Week 76).Time frame: 76 weeks after randomization
  • AddedBaseline-adjusted Serum Levels of GFR-alpha-1 at the End of the Treatment Period (Week 76).Time frame: 76 weeks after randomization
  • AddedBaseline-adjusted Serum Levels of IL-1RT1 at the End of the Treatment Period (Week 76).Time frame: 76 weeks after randomization
  • …and 37 more, on the record history on ClinicalTrials.gov ↗
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Active, not recruiting→Completed
    Results posted
    Study completion Oct 31, 2026→Oct 15, 2026 (now actual)
    Enrollment 40 (estimated)→35 (actual)
    Primary outcomes 3 edited, 20 added
    What changed in the outcomes
    • EditedBaseline-adjusted iGFR at 8 weeks after randomizationWeeks After RandomizationTime frame: 8 weeks after randomization
    • EditedBaseline-adjusted iGFR at the endEnd of the drug washDrug Wash-out periodPeriodTime frame: 84 weeks after randomization
    • EditedBaseline-adjusted levelsSerum Levels of serum biomarkers of increased ESKD riskCD160 at the endEnd of the drug Drug-wash-out periodPeriod (Week 84).Time frame: 84 weeks after randomization
    • AddedBaseline-adjusted Serum Levels of CD27 at the End of the Drug-wash-out Period (Week 84).Time frame: 84 weeks from randomization
    • AddedBaseline-adjusted Serum Levels of DLL1 at the End of the Drug-wash-out Period (Week 84).Time frame: 84 weeks from randomization
    • AddedBaseline-adjusted Serum Levels of EDA2R at the End of the Drug-wash-out Period (Week 84).Time frame: 84 weeks from randomization
    • AddedBaseline-adjusted Serum Levels of EFNA4 at the End of the Drug-wash-out Period (Week 84).Time frame: 84 weeks from randomization
    • AddedBaseline-adjusted Serum Levels of EPHA2 at the End of the Drug-wash-out Period (Week 84).Time frame: 84 weeks from randomization
    • AddedBaseline-adjusted Serum Levels of GFR-alpha-1 at the End of the Drug-wash-out Period (Week 84).Time frame: 84 weeks from randomization
    • AddedBaseline-adjusted Serum Levels of IL-1RT1 at the End of the Drug-wash-out Period (Week 84).Time frame: 84 weeks from randomization
    • AddedBaseline-adjusted Serum Levels of KIM1 at the End of the Drug-wash-out Period (Week 84).Time frame: 84 weeks from randomization
    • AddedBaseline-adjusted Serum Levels of LAYN at the End of the Drug-wash-out Period (Week 84).Time frame: 84 weeks from randomization
    • AddedBaseline-adjusted Serum Levels of LTBR at the End of the Drug-wash-out Period (Week 84).Time frame: 84 weeks from randomization
    • AddedBaseline-adjusted Serum Levels of PI3 at the End of the Drug-wash-out Period (Week 84).Time frame: 84 weeks from randomization
    • AddedBaseline-adjusted Serum Levels of PVRL4 at the End of the Drug-wash-out Period (Week 84).Time frame: 84 weeks from randomization
    • AddedBaseline-adjusted Serum Levels of RELT at the End of the Drug-wash-out Period (Week 84).Time frame: 84 weeks from randomization
    • AddedBaseline-adjusted Serum Levels of SYND1 at the End of the Drug-wash-out Period (Week 84).Time frame: 84 weeks from randomization
    • AddedBaseline-adjusted Serum Levels of TNFR1 at the End of the Drug-wash-out Period (Week 84).Time frame: 84 weeks from randomization
    • AddedBaseline-adjusted Serum Levels of TNFR2 at the End of the Drug-wash-out Period (Week 84).Time frame: 84 weeks from randomization
    • AddedBaseline-adjusted Serum Levels of TNFRSF10A at the End of the Drug-wash-out Period (Week 84).Time frame: 84 weeks from randomization
    • AddedBaseline-adjusted Serum Levels of TNFRSF4 at the End of the Drug-wash-out Period (Week 84).Time frame: 84 weeks from randomization
    • AddedBaseline-adjusted Serum Levels of TNFRSF6B at the End of the Drug-wash-out Period (Week 84).Time frame: 84 weeks from randomization
    • AddedBaseline-adjusted Serum Levels of WFDC2 at the End of the Drug-wash-out Period (Week 84).Time frame: 84 weeks from randomization
    Secondary outcomes 22 edited, 8 added, 37 more
    What changed in the outcomes
    • EditedBaseline-adjusted iGFReGFR-SCr at the endEnd of treatmentthe Wash-out PeriodTime frame: 76 weeks after randomization → 84 weeks after randomization
    • EditedBaseline-adjusted iGFR at the endEnd of treatmentTreatmentTime frame: 76 weeks after randomization
    • EditedBaseline-adjusted eGFR-SCr at 8 weeks after randomizationWeeks After RandomizationTime frame: 8 weeks after randomization
    • EditedBaseline-adjusted eGFR-SCrCysC at the end of treatment8 Weeks After RandomizationTime frame: 76 weeks after randomization → 8 weeks after randomization
    • EditedBaseline-adjusted eGFR-SCrCysC at the endEnd of treatmentthe Wash-out PeriodTime frame: 76 weeks after randomization → 84 weeks after randomization
    • EditedBaseline-adjusted eGFR-SCruAER at the endEnd of the washWash-out periodPeriodTime frame: 84 weeks after randomization
    • EditedBaseline-adjusted eGFR-CysCuAER at 8 weeks after randomizationWeeks After RandomizationTime frame: 8 weeks after randomization
    • EditedBaseline-adjusted eGFR-CysCSCr at the endEnd of treatmentTreatmentTime frame: 76 weeks after randomization
    • EditedBaseline-adjusted eGFR-CysC at the endEnd of treatmentTreatmentTime frame: 76 weeks after randomization
    • EditedBaseline-adjusted eGFR-CysCuAER at the endEnd of the wash-out periodTreatmentTime frame: 84 weeks after randomization → 76 weeks after randomization
    • EditedBaseline-adjusted uAERCreatinine Clearance at 8 weeks after randomizationWeeks After RandomizationTime frame: 8 weeks after randomization
    • EditedBaselineWeek 8-adjusted uAERiGFR at the endEnd of treatmentTreatmentTime frame: 76 weeks after randomization
    • EditeduAERWeek 8-adjusted eGFR-SCr at the endEnd of treatmentTreatmentTime frame: 76 weeks after randomization → 76 weeks from randomization
    • EditedBaselineWeek 8-adjusted uAER at the endEnd of the wash-out periodTreatmentTime frame: 84 weeks after randomization → 76 weeks after randomization
    • EditedBaseline-adjusted creatinine clearanceERPF at 8 weeks after randomizationWeeks After RandomizationTime frame: 8 weeks after randomization
    • EditedBaseline-adjusted ERPFAfferent Renal Arteriolar Resistance at 8 weeks after randomizationWeeks After RandomizationTime frame: 8 weeks after randomization
    • EditedBaseline-adjusted afferent renal arteriolar resistanceEfferent Renal Arteriolar Resistance at 8 weeks after randomizationWeeks After RandomizationTime frame: 8 weeks after randomization
    • EditedBaseline-adjusted efferent renal arteriolar resistanceGlomerular Hydrostatic Pressure at 8 weeks after randomizationWeeks After RandomizationTime frame: 8 weeks after randomization
    • EditedBaseline-adjusted glomerular hydrostatic pressureGlomerular Filtration Pressure at 8 weeks after randomizationWeeks After RandomizationTime frame: 8 weeks after randomization
    • EditedeGFR-SCr trajectoryTrajectoryTime frame: 8 to 76 weeks from randomization
    • EditedeGFR-SCys trajectoryTrajectoryTime frame: 8 to 76 weeks from randomization
    • EditedBaselineWeek 8-adjusted levels of serum biomarkers of increased ESKD riskeGFR-CysC at the endEnd of treatmentTreatmentTime frame: 76 weeks after randomization
    • AddedBaseline-adjusted Serum Levels of CD160 at the End of the Treatment Period (Week 76).Time frame: 76 weeks after randomization
    • AddedBaseline-adjusted Serum Levels of CD27 at the End of the Treatment Period (Week 76).Time frame: 76 weeks after randomization
    • AddedBaseline-adjusted Serum Levels of DLL1 at the End of the Treatment Period (Week 76).Time frame: 76 weeks after randomization
    • AddedBaseline-adjusted Serum Levels of EDA2R at the End of the Treatment Period (Week 76).Time frame: 76 weeks after randomization
    • AddedBaseline-adjusted Serum Levels of EFNA4 at the End of the Treatment Period (Week 76).Time frame: 76 weeks after randomization
    • AddedBaseline-adjusted Serum Levels of EPHA2 at the End of the Treatment Period (Week 76).Time frame: 76 weeks after randomization
    • AddedBaseline-adjusted Serum Levels of GFR-alpha-1 at the End of the Treatment Period (Week 76).Time frame: 76 weeks after randomization
    • AddedBaseline-adjusted Serum Levels of IL-1RT1 at the End of the Treatment Period (Week 76).Time frame: 76 weeks after randomization
    • …and 37 more, on the record history on ClinicalTrials.gov ↗
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04929379
Lead sponsor
Alessandro Doria
Responsible party
Alessandro Doria (Senior Investigator and Professor of Medicine, Joslin Diabetes Center) — Sponsor-investigator
First posted
Jun 18, 2021
Start date
Jan 4, 2022
Primary completion
May 1, 2025
Completion
Oct 15, 2026
Results posted
Nov 10, 2026
Last update
Nov 10, 2026

Study contacts

Alessandro Doria, MD PhD MPH
principal investigator · Joslin Diabetes Center
Michael Mauer, MD
principal investigator · University of Minnesota

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fenofibrate

Start the discussion